Agilent Technologies Life Sciences and Diagnostics Markets — Net revenue decreased by 10.1% to $679.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 4.9%, from $647.00M to $679.00M. Over 2 years (FY 2023 to FY 2025), Life Sciences and Diagnostics Markets — Net revenue shows relatively stable performance with a -1.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates growing market share or higher demand for the segment's product portfolio, while a decrease may signal competitive pressure or market saturation.
This represents the total gross sales generated by the Life Sciences and Diagnostics business segment after deducting re...
Standard revenue reporting for life science tool manufacturers, comparable to peers in the diagnostics and analytical instrumentation space.
a_segment_life_sciences_and_diagnostics_markets_net_revenue| Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $695.00M | $695.00M | $695.00M | $695.00M | $620.00M | $604.00M | $585.00M | $657.00M | $647.00M | $654.00M | $670.00M | $755.00M | $679.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -10.8% | -2.6% | -3.1% | +12.3% | -1.5% | +1.1% | +2.4% | +12.7% | -10.1% |
| YoY Change | — | — | — | — | -10.8% | -13.1% | -15.8% | -5.5% | +4.4% | +8.3% | +14.5% | +14.9% | +4.9% |